cytarabine has been researched along with Kidney Failure in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, K; Gibbons, JA; Marier, JF; Vasilinin, G; Wang, Q | 1 |
| Arcani, R; Colle, J; Costello, RT; Fanciullino, R; Farnault, L; Ivanov, V; Jourde-Chiche, N; Mercier, C; Pourroy, B; Roche, P; Venton, G | 1 |
| Hidaka, T; Koga, H; Miyako, K; Suga, N; Takahashi, N | 1 |
| Boula, AM; Christoforidou, AV; Foudoulakis, AM; Mantadakis, E; Samonis, G; Xilouri, IM | 1 |
| Baars, JW; de Glas-Vos, CW; Rodenhuis, S; Thomas, BL; van der Lelie, H; van Dijk, MA; van Oers, RH; von dem Borne, AE | 1 |
| Damon, LE; Linker, CA; Ries, CA; Rugo, HS; Smith, GA | 1 |
1 review(s) available for cytarabine and Kidney Failure
| Article | Year |
|---|---|
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Hemolytic-Uremic Syndrome; Humans; Hypertension; Immunoglobulins, Intravenous; Male; Middle Aged; Plasma; Remission Induction; Renal Insufficiency; Retinal Vein Occlusion; Thiotepa; Thrombocytopenia; Transplantation, Autologous; Vincristine | 1995 |
5 other study(ies) available for cytarabine and Kidney Failure
| Article | Year |
|---|---|
Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Renal Insufficiency; Treatment Outcome | 2019 |
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Renal Insufficiency; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning | 2019 |
Improving circulatory disturbance in transient abnormal myelopoiesis.
Topics: Antimetabolites, Antineoplastic; Blood Transfusion; Cytarabine; Down Syndrome; Fatal Outcome; GATA1 Transcription Factor; Humans; Hypertension, Pulmonary; Infant, Newborn; Infant, Newborn, Diseases; Liver Failure; Male; Mutation; Myelopoiesis; Renal Insufficiency | 2012 |
Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Fatal Outcome; Hepatic Veno-Occlusive Disease; Humans; Hypoalbuminemia; Leukemia, Myelomonocytic, Chronic; Male; Paresis; Renal Insufficiency; Thrombocytopenia; Vincristine | 2005 |
High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Nervous System Diseases; Renal Insufficiency; Retrospective Studies; Risk Factors | 1997 |